The plasma‐soluble CSF1R level is a promising prognostic indicator for pediatric Langerhans cell histiocytosis

Abstract

AbstractLangerhans cell histiocytosis (LCH) is a rare hematologic neoplasm characterized by the clonal proliferation of Langerhans‐like cells. Colony‐stimulating factor 1 receptor (CSF1R) is a membrane‐bound receptor that is highly expressed in LCH cells and tumor‐associated macrophages. In this study, a soluble form of CSF1R protein (sCSF1R) was identified by plasma proteome profiling, and its role in evaluating LCH prognosis was explored. We prospectively measured plasma sCSF1R levels in 104 LCH patients and 10 healthy children using ELISA. Plasma sCSF1R levels were greater in LCH patients than in healthy controls (p < .001) and significantly differed among the three disease extents, with the highest level in MS RO+ LCH patients (p < .001). Accordingly, immunofluorescence showed the highest level of membrane‐bound CSF1R in MS RO+ patients. Furthermore, the plasma sCSF1R concentration at diagnosis could efficiently predict the prognosis of LCH patients treated with standard first‐line treatment (AUC = 0.782, p < .001). Notably, dynamic monitoring of sCSF1R levels could predict relapse early in patients receiving BRAF inhibitor treatment. In vitro drug sensitivity data showed that sCSF1R increased resistance to Ara‐C in THP‐1 cells expressing ectopic BRAF‐V600E. Overall, the plasma sCSF1R level at diagnosis and during follow‐up is of great clinical importance in pediatric LCH patients.